What exactly changed in the Feb 3, 2026 THC analyst rating?

UBS **reiterated a Buy** on Tenet Healthcare (THC) on Feb 3, 2026. The call was maintained rather than upgraded or downgraded. StreetInsider reported a small price move of **-0.14% ($-0.28)** at publication.

Did UBS provide a new THC price target with the maintained Buy?

No. The UBS note published on Feb 3, 2026 did not include a new THC price target. Investors must use prior targets and company updates for valuation work.

How should investors interpret a maintained Buy for Tenet Healthcare?

A maintained Buy signals analyst confidence in Tenet’s outlook without fresh conviction. Use this THC analyst rating as one input and weigh company news, valuation, and risk tolerance before repositioning.

How does the Meyka Grade relate to the UBS call on THC?

Meyka AI rates THC with a grade of **B+**, reflecting benchmark, sector, growth, metrics, and consensus. The UBS maintained Buy supports this grade but is not the only factor to consider.

Analyst Ratings

UBS Reiterates Buy for Tenet Healthcare (THC) Feb 3, 2026

ByDanny Kontos February 4, 2026February 4, 2026

UBS maintained a Buy rating on Tenet Healthcare Corporation (THC) on Feb 3, 2026. This update is the core THC analyst rating action this week. UBS left its view unchanged and the market reaction was muted with a -0.14% ($-0.28) intraday move. Investors should treat this maintained Buy as a signal of confidence, not a fresh upgrade or downgrade.